DOCSLIB.ORG

Suffolk County Heroin and Opiate Epidemic Advisory Panel 2020 Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Suffolk County Heroin and Opiate Epidemic Advisory Panel 2020 Report SUFFOLK COUNTY HEROIN AND OPIATE EPIDEMIC ADVISORY PANEL 2020 REPORT Presented by Suffolk County Legislator Sarah Anker, Panel Chair December 2020 Hauppauge, NY 1 Table of Contents Membership …………………………………………………………..……………………………….… 4 Introduction …………………………………………………………………………………………….…6 Letter from the Chairwoman ……………………………………………………………………..…….....7 Education, Prevention & Treatment ……………………………………………………………………...10 Law Enforcement ………………………………………………………………………………………...20 Statistics Suffolk County Medical Examiner………………………………………………………….........25 Suffolk County Police Department……………………………………………………………….29 DASH Center……………………………………………………………………………………..32 Long Island Council on Alcoholism and Drug Dependence 2020 Report………………………..34 Long Island Council on Alcoholism and Drug Dependence 2019 Report………………………..43 Mass Spectrometer………………………………………………………………………………………..51 Suffolk County Drug Treatment Courts…………………………………………………………………..52 Legislation and Legal Action …………………………..……..……………………………………..…...53 Initiatives and Recommendations………………………………………………………………………...61 Panel Meetings 2020 Meeting Schedule ………………………………………….……………………………...66 February 7, 2020 ………………………………………………………………………………..67 May 8, 2020 …………………………………………………………………………………….71 July 10, 2020 ……………………………………………..…………………………....………..76 November 13, 2020 …………………………………………………..………………………....81 Public Hearings September 23, 2020 ………………………………………….....................................................95 October 22, 2020 ……………………………………………………………………………….98 Suffolk County Health Department Resources 2020 Suffolk County Directory of Behavioral Health Services ………………………………..101 Suffolk County Community of Solutions Referral List ………………………………………...125 Appendix Appendix I - Legislation and Amendments ……………………………………………...…… 128 Appendix II – Glossary of Terms ………………………………………………………..…….145 Appendix III – Letter to MTA/LIRR Representatives……………….. ……………………….150 Appendix IV – Letter to Senator Kenneth LaValle Regarding Funding for the NYS OASAS..152 Appendix V – Letter to Congressman Lee Zeldin Regarding a Future Stimulus Package….... 154 Appendix VI –Letter to Commissioner Arlene González-Sánchez Regarding Telehealth and 2 Virtual Care Options for Medicare and Medicaid Beneficiaries Plan Task Force Report ……...………………………………………………………..…156 Appendix VII – New York State Office of Addiction Services and Supports Statewide Comprehensive Place 2020-2024……………………………….…………….158 Appendix VIII– Joint Senate Task Force on Opioids, Addiction, and Overdose Prevention Report…………………………………………………..159 Appendix IX– United States Senate Finance Committee Report Findings from the Investigation of the Opioid Manufacturer’s Financial Relationships with Patient Advocacy Groups and other Tax-Exempt Entities..…………………..160 Appendix X– Center for Disease Control Annual Surveillance Report of Drug-Related Risks and Outcomes..………………………………………………………………..161 Appendix XI– Center for Disease Control Health Advisory: Increase in Fatal Overdoses Across the United States Driven by Synthetic Opioids Before and During the COVID-19 Pandemic……………………………………………………..162 Appendix XII– Nassau County Opioid Crisis Action Plan Task Force 2019 Report…..……...163 Appendix XIII– Long Island Council on Alcoholism and Drug Dependence H.E.R.E Flyer....164 3 Annual Report from the Suffolk County Heroin and Opiate Epidemic Advisory Panel December 2020 Report Panel Membership Legislator Sarah S. Anker, Advisory Panel Chairwoman and designee of Presiding Officer Rob- ert Calarco of the Suffolk County Legislature Legislator Tom Donnelly, Chairman of the Public Safety Committee of the Suffolk County Legislature Legislator Kevin McCaffrey, Chairman of the Education and Labor Committee of the Suf- folk County Legislature Legislator Samuel Gonzalez, designee of Legislator Sarah S. Anker, Chairwoman of the Seniors and Human Services Committee of the Suffolk County Legislature Commissioner Dr. Gregson Pigott, MD., Suffolk County Health Department Ann Marie Csorny, LCSW, Director of the Suffolk County Department of Health Services Division of Community Mental Hygiene Services Commissioner Geraldine Hart, Suffolk County Police Department Sheriff Errol D. Toulon, Jr., Suffolk County Sheriff’s Department District Attorney Tim Sini, Suffolk County District Attorney’s Office Director Andrea Neubauer, Suffolk County Department of Probation Dr. Michael J. Caplan, MD., Chief Medical Examiner, Suffolk County Robert McConville, Former Commissioner, Selden Fire District representative for Fire Chief Council of Suffolk County Antonette Whyte-Etere, LCSW-R, CASAC, Regional Coordinator, NYS OASAS Long Island Regional Office Dr. Julie Lutz, PhD Chief Operating Officer for East Suffolk BOCES and panel representative for the Suffolk County Superintendent’s Association 4 Dr. Richard Rosenthal, MD, Stony Brook University Hospital Division of Psychiatry Dr. Kristie Golden, PhD, LMHC, CRC, Associate Director of Operations for Neurosciences at Stony Brook University Hospital David Cohen, LCSW, Director of Outpatient Addiction Services at Eastern Long Island Hospital Janine Logan, Senior Director of Communications and Population Health, Nassau-Suffolk Hospi- tal Council (NSHC) Dr. Patrick O’Shaughnessy, DO, Catholic Health Services of Long Island Dr. Jeffrey Reynolds, PhD, CEAP, SAP, President/CEO Family and Children’s Association (FCA) Steve Chassman, LCSW, CASAC, Executive Director of Long Island Council on Alcoholism and Drug Dependence, Inc. (LICADD) Mary Silberstein, LCSW-R, CASAC, Chair of Suffolk County Communities of Solution Anthony Rizzuto LMSW, CASAC, Executive Director & Founder of Families in Support of Treatment (FIST) Patricia Ferrandino, LCSW, CASAC, Past President of the Quality Consortium of Suffolk and representative of Family Service League Pamela Mizzi, MS, CASAC, LMHC, Director of Prevention at the Long Island Prevention Resource Center John Venza, LCSW-R, LMHC, Director of Outreach House Steven Miller, LCSW, representative from Hope House Ministries Patrick Policastro, Executive Director of the North Shore Youth Council (NSYC) Veronica Carrier, member of the general public appointed by the Suffolk County Legislature, CN Guidance and Counseling 5 Introduction Resolution 704-2017, sponsored by Suffolk County Legislator Sarah Anker, to establish a perma- nent Suffolk County Heroin and Opiate Epidemic Advisory Panel was approved unanimously by the Suffolk County Legislature and signed by Suffolk County Executive Steve Bellone on Sep- tember 25, 2017. The goal of the panel is to provide ongoing guidance and input to the county in regard to combating the opioid epidemic. The panel utilizes an interdisciplinary approach, focus- ing on preventative education, enhancement of law enforcement efforts, and aiding in treatment and rehabilitation. The original Suffolk County Heroin and Opiate Epidemic Advisory Panel was formed in 2010 via IR 413-2010. Several panel members met again in 2016 to identify the progress that had been made and discuss where additional focus might be needed. The establishment of the current per- manent panel is due to the ever-evolving nature of the opioid epidemic that requires a continuous commitment to focusing on priorities. The permanent panel will continue to meet and work to- ward achieving their shared goals. The panel includes members of the Suffolk County Legislature, representatives from Suffolk County Law Enforcement including the Police Department, Sheriff’s Department, Probation, the Suffolk County Department of Health, the Suffolk County Medical Examiner’s office, and local rehabilitation and treatment providers, advocacy groups, hospitals, and the Suffolk County Super- intendent’s Association. The panel meets quarterly and holds two public hearings annually. As per the resolution, a report will be filed with the Legislature in December of each year. As leaders in their respective fields, the panel members bring a diverse array of experiences and perspectives to the group, both personally and professionally. The energy, passion and dedication of each panel member is evident throughout the process. The panel brings communities and agen- cies together, focusing the field’s collective energies and maximizing the power of collaboration. The 2020 Report highlights addiction initiatives that have been advanced this year, as well as for- mer initiatives that the panel will continue to advocate for and support. It is recognized that this is an ever-evolving process and the panel is committed to continuing to work toward implementing new initiatives and supporting vital programs that will reduce the number of drug overdoses and fatalities in Suffolk County. 6 Letter from Panel Chairwoman Legislator Sarah Anker As the representative for Presiding Officer Robert Calarco, and panel chairwoman, I must com- mend Suffolk County’s Heroin and Opiate Epidemic Advisory Panel members, who have greatly contributed their time and knowledge in addressing the issue of drug addiction and mental health support. Through the collaboration of government agencies, medical professionals, law enforce- ment, the court system, educational institutions and advocates, the panel continues to provide guidance and insight as the county addresses the drug addiction epidemic. There have been 3 waves in the opioid drug addiction epidemic. The first wave started in the 1990, and began with the overprescribing of opioid drugs. In 2010, the second wave involved in- creased overdose deaths due to heroin addiction following restrictions on opioid prescriptions.
Load more

Recommended publications
  • The Effects of Recreational Marijuana Legislation on the Opioid Epidemic in Washington State" (2018)
    Claremont Colleges Scholarship @ Claremont CMC Senior Theses CMC Student Scholarship 2018 The ffecE ts of Recreational Marijuana Legislation on the Opioid Epidemic in Washington State Steven Dickerson Claremont McKenna College Recommended Citation Dickerson, Steven, "The Effects of Recreational Marijuana Legislation on the Opioid Epidemic in Washington State" (2018). CMC Senior Theses. 1757. http://scholarship.claremont.edu/cmc_theses/1757 This Open Access Senior Thesis is brought to you by Scholarship@Claremont. It has been accepted for inclusion in this collection by an authorized administrator. For more information, please contact [email protected]. Claremont McKenna College ​ ​ ​ ​ The Effects of Recreational Marijuana Legislation on the Opioid Epidemic ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ in Washington State ​ ​ ​ ​ Submitted to ​ ​ Professor David Bjerk ​ ​ ​ ​ By: Steven Reid Dickerson Jr. ​ ​ ​ ​ ​ ​ ​ ​ for Senior Thesis ​ ​ Fall 2017 ​ ​ December 4th ​ ​ Table of Contents ​ ​ ​ ​ Abstract 2 Acknowledgments 3 Introduction 4 Literature Summary 7 ​ ​ A History of the Opioid Epidemic 7 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ The History of Marijuana Legislation in the United States 10 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ The Effect of Marijuana Laws on Opioid Usage 12 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Data 13 Opioid Overdose Crude Death Rate 14 ​ ​ ​ ​ ​ ​ ​ ​ Self-Reported Drug Usage 15 ​ ​ ​ ​ Treatment Admissions 15 ​ ​ Empirical Strategy 16 ​ ​ Analysis 19 Opioid Overdose Crude Death Rates 19 ​ ​ ​ ​ ​ ​ ​ ​ Self-Reported Opioid Usage 24 ​ ​ ​ ​
    [Show full text]
  • Methadone Hydrochloride Tablets, USP) 5 Mg, 10 Mg Rx Only
    ROXANE LABORATORIES, INC. Columbus, OH 43216 DOLOPHINE® HYDROCHLORIDE CII (Methadone Hydrochloride Tablets, USP) 5 mg, 10 mg Rx Only Deaths, cardiac and respiratory, have been reported during initiation and conversion of pain patients to methadone treatment from treatment with other opioid agonists. It is critical to understand the pharmacokinetics of methadone when converting patients from other opioids (see DOSAGE AND ADMINISTRATION). Particular vigilance is necessary during treatment initiation, during conversion from one opioid to another, and during dose titration. Respiratory depression is the chief hazard associated with methadone hydrochloride administration. Methadone's peak respiratory depressant effects typically occur later, and persist longer than its peak analgesic effects, particularly in the early dosing period. These characteristics can contribute to cases of iatrogenic overdose, particularly during treatment initiation and dose titration. In addition, cases of QT interval prolongation and serious arrhythmia (torsades de pointes) have been observed during treatment with methadone. Most cases involve patients being treated for pain with large, multiple daily doses of methadone, although cases have been reported in patients receiving doses commonly used for maintenance treatment of opioid addiction. Methadone treatment for analgesic therapy in patients with acute or chronic pain should only be initiated if the potential analgesic or palliative care benefit of treatment with methadone is considered and outweighs the risks. Conditions For Distribution And Use Of Methadone Products For The Treatment Of Opioid Addiction Code of Federal Regulations, Title 42, Sec 8 Methadone products when used for the treatment of opioid addiction in detoxification or maintenance programs, shall be dispensed only by opioid treatment programs (and agencies, practitioners or institutions by formal agreement with the program sponsor) certified by the Substance Abuse and Mental Health Services Administration and approved by the designated state authority.
    [Show full text]
  • Medications to Treat Opioid Use Disorder Research Report
    Research Report Revised Junio 2018 Medications to Treat Opioid Use Disorder Research Report Table of Contents Medications to Treat Opioid Use Disorder Research Report Overview How do medications to treat opioid use disorder work? How effective are medications to treat opioid use disorder? What are misconceptions about maintenance treatment? What is the treatment need versus the diversion risk for opioid use disorder treatment? What is the impact of medication for opioid use disorder treatment on HIV/HCV outcomes? How is opioid use disorder treated in the criminal justice system? Is medication to treat opioid use disorder available in the military? What treatment is available for pregnant mothers and their babies? How much does opioid treatment cost? Is naloxone accessible? References Page 1 Medications to Treat Opioid Use Disorder Research Report Discusses effective medications used to treat opioid use disorders: methadone, buprenorphine, and naltrexone. Overview An estimated 1.4 million people in the United States had a substance use disorder related to prescription opioids in 2019.1 However, only a fraction of people with prescription opioid use disorders receive tailored treatment (22 percent in 2019).1 Overdose deaths involving prescription opioids more than quadrupled from 1999 through 2016 followed by significant declines reported in both 2018 and 2019.2,3 Besides overdose, consequences of the opioid crisis include a rising incidence of infants born dependent on opioids because their mothers used these substances during pregnancy4,5 and increased spread of infectious diseases, including HIV and hepatitis C (HCV), as was seen in 2015 in southern Indiana.6 Effective prevention and treatment strategies exist for opioid misuse and use disorder but are highly underutilized across the United States.
    [Show full text]
  • The Opioid Epidemic: What Labs Have to Do with It?
    The Opioid Epidemic: What labs have to do with it? Ewa King, Ph.D. Associate Director of Health RIDOH State Health Laboratories Analysis. Answers. Action. www.aphl.org Overview • Overdose trends • Opioids and their effects • Analytical testing approaches • Toxicology laboratories Analysis. Answers. Action. www.aphl.org Opioid overdose crisis 1 Analysis. Answers. Action. www.aphl.org Opioid overdose crisis 2 Analysis. Answers. Action. www.aphl.org Opiates and Opioids • Opiates vs. Opioids • Opiates: Naturally occurring, derived from the poppy plant • Opioids: “Opiate-like” drugs in effects, not chemical structure Includes opiates • Narcotic analgesics • CNS depressants • DEA Schedule I or II controlled substances • Additive effect with other CNS depressant drugs Analysis. Answers. Action. www.aphl.org Efficacy of Opioids • How do opioids work? • Bind with opioid receptors • Brain, spinal cord, GI tract, and throughout the body • Pain, emotion, breathing, movement, and digestion Opioid Receptor Analysis. Answers. Action. www.aphl.org Effects of Opioids Physiological Psychological • Pain relief • Drowsiness/ sedation • Cough suppression • Mental confusion • GI motility • Loss of memory • Respiratory depression • Lethargy/ apathy • Pupillary constriction • Euphoria/ tranquility • Itching • Mood swings • Constipation • Depression • Dependence • Withdrawal • Dependence Analysis. Answers. Action. www.aphl.org Opiates 1 Opiates • Naturally occurring alkaloids Opium • Latex from the opium poppy plant Codeine: • Mild to moderate pain • Antitussive Morphine: • Severe pain • Metabolite of codeine and heroin Analysis. Answers. Action. www.aphl.org Opiates 2 Semi-synthetic Opiates: • Synthesized from a natural opiate Heroin: • Schedule I narcotic Hydrocodone (Vicodin): • Mild to moderate pain • Metabolizes to hydromorphone (Dilaudid) Oxycodone (Oxycontin/Percocet): • Moderate to severe pain • Metabolizes to oxymorphone (Opana) Analysis. Answers. Action.
    [Show full text]
  • Washington DC's Opioid Strategic Plan
    Updated as of March 2019 Letter from Mayor Muriel Bowser Too many of our neighbors in Washington, DC lose their lives or family members and friends to a substance use disorder. Many of these cases involve opioid overdoses. The District’s multi-stakeholder, public health approach has yielded progress in saving lives and reducing fatal overdoses, but there is still work to be done to reduce the impact of the epidemic on our city. “LIVE.LONG.DC,” Washington, DC’s Strategic Plan to Reduce Opioid Use, Misuse and Related Deaths is our blueprint for how best to continue moving forward with urgency and thoughtfulness as we work towards reversing fatal opioid overdoses. The Plan reflects the input of a cross-section of public and private partners, including DC government agencies, hospital leaders, physicians, substance use disorder treatment providers, community-based service providers, federal partners, and individuals in recovery. The updated Plan offers a comprehensive look at prevention, treatment, and recovery, detailing our goals and accompanying strategies to end Washington, DC’s opioid epidemic. Our Plan offers additional details on how these goals and strategies will be accomplished in order to ensure District residents can thrive and move forward with the support they need. Working together, the implementation of LIVE.LONG.DC has resulted in some early successes, which include: Reversing more than 1,000 overdoses through naloxone kits and training residents in naloxone use; Increasing the capacity of practitioners to provide Buprenorphine-based medication-assisted treatment (MAT); Monitoring trends in opioid use and tailoring responses and interventions based on real-time data; Increasing testing capacity via surveillance of synthetic opioids in the District, both to discover new synthetic opioids as well as characterize those currently present; and Revising innovative public education campaigns targeting those who are most likely to overdose on heroin and to educate young people on the dangers of misusing prescription opioids.
    [Show full text]
  • Opiate/ Heroin Working Group Final Report
    OPIATE/ HEROIN WORKING GROUP FINAL REPORT United States Attorney’s Offices For the Southern and Northern Districts of Mississippi February 28. 2017 HEROIN/OPIATE WORKING GROUP FINAL REPORT Law Enforcement and Data Group Recommendation No. 1: Implement a comprehensive data collection and dissemination program Recommendation No. 2: Heroin (Opiate) Involved Death Investigation Task Force Recommendation No. 3: Greater distribution and training on use of Naloxone Recommendation No. 4: Mandate greater reporting of overdoses and naloxone administration Recommendation No. 5: Expand and advertise availability of the dropbox program Medical Issues Group Recommendation No. 1: Adopt CDC Guidelines Recommendation No. 2: Continuing Medical Education Recommendation No. 3: Upgrades to the Prescription Monitoring Program Recommendation No. 4: Addiction Treatment Education Recommendation No. 5: Review Funding Issues for Alternative Treatments Recommendation No. 6: Limitations on Prescriptions Recommendation No. 7: Mandate increased use of PMP Recommendation No. 8: Change the definition of Pain Management Clinic Recommendation No. 9: IDs for Controlled Substance Prescriptions Treatment and Overdose Prevention Group Recommendation No. 1: More Funding for Treatment Recommendation No. 2: Youth/Juvenile Detention Systems Recommendation No. 3: Expand the availability and use of Vivitrol Recommendation No. 4: Drug Courts and Rentry programs Recommendation No. 5: Public Education and Awareness HEROIN/OPIATE WORKING GROUP FINAL REPORT The United States Attorney’s Offices for the Northern and Southern Districts of Mississippi convened an Opiate/Heroin Working Group in June 2016. At the initial meeting at the Mississippi Bureau of Narcotics (“MBN”) Headquarters, representatives from the medical, pharmaceutical, mental health, law enforcement, judiciary and many other specialties attended a full day symposium to begin the discussion about a comprehensive approach to the opiate and heroin crisis in the nation and in our state.
    [Show full text]
  • The Biden-Harris Administration's Statement of Drug Policy Priorities
    EXECUTIVE OFFICE OF THE PRESIDENT OFFICE OF NATIONAL DRUG CONTROL POLICY Washington, DC 20503 The Biden-Harris Administration’s Statement of Drug Policy Priorities for Year One The overdose and addiction crisis has taken a heartbreaking toll on far too many Americans and their families. Since 2015, overdose death numbers have risen 35 percent, reaching a historic high of 70,630 deaths in 2019.1 This is a greater rate of increase than for any other type of injury death in the United States.2 Though illicitly manufactured fentanyl and synthetic opioids other than methadone (SOOTM) have been the primary driver behind the increase, overdose deaths involving cocaine and other psychostimulants, like methamphetamine,3 have also risen in recent years, particularly in combination with SOOTM. New data suggest that COVID-19 has exacerbated the epidemic,4, 5 and increases in overdose mortality6 have underscored systemic inequities in our nation’s approach to criminal justice and prevention, treatment, and recovery. President Biden has made clear that addressing the overdose and addiction epidemic is an urgent priority for his administration. In March, the President signed into law the American Rescue Plan, which appropriated nearly $4 billion to enable the Substance Abuse and Mental Health Services Administration and the Health Resources and Services Administration to expand access to vital behavioral health services. President Biden has also said that people should not be incarcerated for drug use but should be offered treatment instead. The President has also emphasized the need to eradicate racial, gender, and economic inequities that currently exist in the criminal justice system.
    [Show full text]
  • The Opioid Epidemic: a Geography in Two Phases David A
    A report summary from the Economic Research Service April 2021 The Opioid Epidemic: A Geography in Two Phases David A. McGranahan and Timothy S. Parker What Is the Issue? Since the late 1990s, an opioid epidemic has afflicted the U.S. population, particularly people in prime working ages of 25-54. Driven by the opioid epidemic, the age-adjusted overall mortality rate from drug overdoses rose from 6.1 per 100,000 people in 1999 to 21.7 per 100,000 in 2017, before dropping to 20.7 per 100,000 in 2018. The drug overdose mortality rate among the prime working age population was 36.5 deaths per 100,000 people in 2018. Among major causes of death in this population, this rate was exceeded only by cancer (40.5 deaths per 100,000) in 2018. What caused this epidemic, and who has been most affected? One view is that economic misfor- tune has driven many working-age people to self-destructive behavior—marked by increasing drug and alcohol abuse and suicide. However, another line of research shows that local economic downturns have been a small factor in the geography of the drug overdose epidemic. A second view faults the widespread introduction of new opioid prescription painkillers, succeeded in recent years by the spread of heroin and powerful synthetics such as fentanyl. This view, which has received less research attention, is the focus of this study. What Did the Study Find? The study found evidence that the introduction and supply of new opioid drugs, whether through prescription painkillers in the 2000s or illicit opioids such as fentanyl in the 2010s, were major drivers of the opioid epidemic.
    [Show full text]
  • The Opioid Crisis and the Black/African American Population: an Urgent Issue
    THE OPIOID CRISIS AND THE BLACK/AFRICAN AMERICAN POPULATION: AN URGENT ISSUE THE OPIOID CRISIS AND THE BLACK/AFRICAN AMERICAN POPULATION: AN URGENT ISSUE U.S. Department of Health and Human Services Substance Abuse and Mental Health Services Administration Office of Behavioral Health Equity Table of Contents Introduction ...................................................................................................................................................... 3 i. Purpose of the Issue Brief ........................................................................................................................ 3 ii. Sources of Information ............................................................................................................................ 4 Opioids in Black/African American Communities: Context .................................................................. 4 i. What Do the National Data Show? ........................................................................................................ 4 ii. Routes to Opioid Misuse and Overdose Deaths: Pain Management, Illicit Drug Use, and Opioid Comorbidities in Black/African American Communities .................................................... 6 iii. Challenges to Prevention, Treatment, and Recovery .......................................................................... 7 Strategies to Address Opioid Misuse and OUD in Black/African American Communities ............ 9 i. Standard Treatment ................................................................................................................................
    [Show full text]
  • Drug Class Review Long-Acting Opioid Analgesics
    Drug Class Review Long-Acting Opioid Analgesics 28:08.08 Opiate Agonists Transdermal Buprenorphine transdermal system (Butrans®) Fentanyl transdermal system (Duragesic®) Oral Buprenorphine oral buccal film (Belbuca®) Hydrocodone ER (Zohydro ER®, Hysingla ER®) Hydromorphone hydrochloride extended-release tablets (Exalgo®) Methadone tablets (Dolophine®) Morphine sulfate controlled-release tablets (MS Contin®, MorphaBond®) Morphine sulfate extended-release capsules (Kadian®) Oxycodone hydrochloride controlled-release tablets (OxyContin®) Oxymorphone hydrochloride extended-release (Opana ER®) Tapentadol extended-release oral tablets (Nucynta ER®) Tramadol hydrochloride extended-release capsule (Conzip, others) Tramadol hydrochloride extended-release tablet (biphasic) (Ultram ER, others) Combination Products Morphine sulfate and naltrexone extended-release capsules (Embeda®) Oxycodone ER/acetaminophen (Xartemis XR®) Final Report March 2016 Review prepared by: Vicki Frydrych, Clinical Pharmacist Melissa Archer, Clinical Pharmacist Justin Tran, PharmD Student Ryan Marcum, PharmD Student University of Utah College of Pharmacy Copyright © 2016 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved. Table of Contents Executive Summary ........................................................................................................................ 3 Introduction ..................................................................................................................................... 5 Table 1. Comparison
    [Show full text]
  • The Effect of Medical Cannabis Legalization on the Medicaid
    The Effect of Medical Cannabis Legalization on the Medicaid Opioid Prescription Rate Nathaniel Downes MMSS Senior Thesis Advisor: Diane Whitmore Schanzenbach ;1 Acknowledgements I would like to thank the MMSS program at Northwestern University for providing me with the opportunity to do this research project, and Professor Joseph Ferrie and Nicole Schneider for all their help through this process. I would also like to thank Professor Diane Schanzenbach for her invaluable advice and support as an advisor; without her expertise I would never have been able to finish this thesis. I also want to thank my family, who have provided me the opportunity to aend Northwestern and have supported me throughout my time here. Lastly, I want to thank my dad, Tom Downes; you have been more helpful than I ever could have hoped a person could be through every step of producing this thesis. You were always there to answer my questions and give me guidance as to how to tackle problems, and I can’t thank you enough for everything you’ve done to help bring this thesis into being. Abstract The opioid epidemic has become one of the most pressing public health issues over the past two decades as both prescription and overdose rates have risen. One proposal to curb the prescription rate of opioids is the use of medical cannabis as a substitute painkiller. This paper examines the effect of medical cannabis on the prescription rate of opioids among Medicaid participants. Using three variations on a difference-in-differences approach, I find that medical cannabis implementation produces a reduction in the Medicaid opioid prescription rate of around 10%, which first appears about a year post-implementation and remains steady in subsequent years.
    [Show full text]
  • Download an Information Sheet on Opiate Use During Pregnancy
    PARENT/FAMILY EDUCATION OPIATE USE DURING PREGNANCY childrensMN.org OPIATES Medications or drugs known as opiates (or narcotics) are commonly prescribed OPIATE USE DURING for pain. The most common names of these drugs include OxyContin, Percocet, PREGNANCY: HOW DOES IT Vicodin, morphine and methadone. Use of opiates during pregnancy often causes AFFECT MOTHERS AND BABIES? complications for mothers as well as complications for babies exposed to opiates in the womb. Illegal opiates like heroin also cause risks for mother and baby. During pregnancy, everything you eat or drink can have an effect on Prescription opiates can be used illegally, or taken at higher doses than prescribed. your unborn baby. This includes Use of any form of opiate can lead to dependency which has been observed medications, drugs, alcohol and in the rapidly increasing number of young women that have developed opiate tobacco. Certain substances are dependency in the past 10 years. Many people who have become dependent on not safe during pregnancy and you prescription opiates are also at risk of using heroin. should review any medications, drugs (over the counter, prescribed The newborn baby exposed to opiates in the womb may have withdrawal and illegal), supplements, or herbs symptoms after being born. When babies have symptoms of withdrawal, they often that you are taking with your need to stay in the hospital longer and may not be able to stay in their mother’s doctor or midwife. By informing room. Instead, they may need the close observation and care that is given in a your care team about ALL drugs special care nursery.
    [Show full text]